علاج خلل الحركة المتأخر المزعج الذي يؤثر على أنشطة الحياة اليومية في المرضى المتلقين للأدوية المضادة للذهان

References

DOI: 10.1016/j.jns.2018.02.010

• In patients with troublesome TS, suppressive agents should be considered.
• Suppressive therapy should be considered when disabilities are at least moderate and interfere with ADLs and QoL, with new VMAT2 inhibitors or TBZ (if both Deut-TBZ and valbenazine are not available) as the first-line treatment, with clonazepam and Ginkgo biloba as second-line, and combined with amantadine if symptoms are still troublesome.
• New generation VMAT2 inhibitors, either Deut-TBZ or valbenazine, should be considered as first-line therapy.